Conquer Cancer Foundation • Cancer.Net • Journal of Clinical Oncology • Journal of Oncology Practice ASCO University • Quality Oncology Practice Initiative (QOPI) • ASCO Connection ASCO: American Society of Clinical Oncology View Sitemap A-Z Indexed Sitemap Advanced Search ASCO SIGN IN Manage Email Subscriptions Username: Create an account Why Be A Member? Password: [question] Remember me Forgot your username or password ? ASCO Membership Directory The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users. To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout. For additional information please review our Privacy Policy . Home About ASCO MyASCO Cancer Portals Products Meetings Donate Join ASCO <#> * Practice & Guidelines * Research Resources * Education & Training * Public Policy * International Affairs * Grants & Awards * MultiMedia * Press Center ASCO Home arrow Meetings arrow Abstracts arrow 2012 Genitourinary Cancers Symposium Bookmark and Share Treatment of metastatic renal cancer with high-dose interleukin-2 after targeted therapy. Print Print this page Sub-category: Renal Cell Cancer Category: Genitourinary Cancer Meeting: 2012 Genitourinary Cancers Symposium Session Type and Session Title: General Poster Session E: Renal Cancer Abstract No: 439 Citation: J Clin Oncol 30, 2012 (suppl 5; abstr 439) Author(s): Robert E. Hawkins, Victoria Galvis, Jonathan Shanks, Neha Dalal, Fiona Thistlethwaite, Andrea Spencer-Shaw; Christie Cancer Research UK, Manchester, United Kingdom; The Christie, Manchester, United Kingdom Abstract Disclosures Abstract: *Background: * High-Dose Interleukin-2 (HD IL2) remains a good option for treatment of metastatic renal cancer. As a first-line treatment, in carefully selected patients, it can produce high rates of response ( OR 50%; CR 25%) (Shablak A et al., J Immunotherapy 2011, 34(1):107-122). Its use after targeted therapies is controversial and there are reports of increased toxicity, particularly an increased incidence of cardiovascular toxicity (and possibly a reduced response rate (Cho DC et al., J Immunotherapy 2009, 32(2):181-520). However, there is potential to use it either in patients who have failed treatment with targeted therapy or as a consolidation therapy after successful treatment with a targeted agent. *Methods: * Here we present the outcomes of 16 patients treated with first-line immunotherapy with HD-IL2 after targeted therapy: of these 8 had been treated after failure of 1-3 lines of targeted therapy and 8 have been treated as consolidation after initial response to sunitinib. The histological characteristics of the tumours all fitted into the “favourable” group as defined previously by us and all had high levels of expression of CAIX (> 80%). All had ECOG PS 0/1, a satisfactory baseline stress echo, an interval of at least 8 weeks from last dose of targeted agent to start of HD-IL2 and at most 2 organs of disease. *Results: * Toxicity is indistinguishable from that of patients without prior treatment and no patient needed inotropic support or admission to intensive care. The number of doses given per cycle was also similar to that in unpretreated patients. Overall the response rates are excellent – with 9/13 evaluable patients having RECIST defined response and 6/13 having a complete remission. To date none of the patients in complete remission have realpsed but follow up is relatively short with the longest being 24 months. The responses have been particularly striking following treatment with mTor inhibitors. *Conclusions: * Overall, HD IL2 can be given safely in carefully selected patients after targeted therapies. It appears to be effective as a salvage therapy and potentially as a consolidation therapy. Updated results will be presented. Associated Presentation(s): 1. Treatment of metastatic renal cancer with high-dose interleukin-2 after targeted therapy. Meeting: 2012 Genitourinary Cancers Symposium Presenter: Robert E. Hawkins Session: General Poster Session E: Renal Cancer (General Poster Session) Other Abstracts in this Sub-Category: 1. Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC). Meeting: 2012 Genitourinary Cancers Symposium Abstract No: 348 First Author: Robert A. Figlin Category: Genitourinary Cancer - Renal Cell Cancer 2. Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. Meeting: 2012 Genitourinary Cancers Symposium Abstract No: 349 First Author: Christopher J. Richards Category: Genitourinary Cancer - Renal Cell Cancer 3. Effect of preoperative antiangiogenic treatment and subsequent discontinuation on angiogenesis in the primary tumor in patients with RCC. Meeting: 2012 Genitourinary Cancers Symposium Abstract No: 350 First Author: Axel Bex Category: Genitourinary Cancer - Renal Cell Cancer More... Abstracts by Robert E. Hawkins: 1. Identification of pre- and post-treatment markers of efficacy in patients with renal cancer treated with MVA-5T4 in a phase III study. Meeting: 2011 ASCO Annual Meeting Abstract No: 2542 First Author: R. Harrop Category: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy - Immunotherapy and Biologic Therapy 2. Sunitinib (SU) treatment (trx) patterns and toxicity in patients (pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK). Meeting: 2011 ASCO Annual Meeting Abstract No: e15150 First Author: J. Wagstaff Category: Genitourinary Cancer - Kidney Cancer 3. A randomized, double-blind phase III study (VEG105192) of pazopanib (paz) versus placebo (pbo) in patients with advanced/metastatic renal cell carcinoma (mRCC): Updated safety results. Meeting: 2011 Genitourinary Cancers Symposium Abstract No: 313 First Author: C. N. Sternberg Category: Genitourinary Cancer - Renal Cell Cancer More... Presentations by Robert E. Hawkins: 1. Treatment of metastatic renal cancer with high-dose interleukin-2 after targeted therapy. Meeting: 2012 Genitourinary Cancers Symposium Presenter: Robert E. Hawkins, PhD, FRCP Session: General Poster Session E: Renal Cancer (General Poster Session) 2. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). Meeting: 2009 ASCO Annual Meeting Presenter: Robert E Hawkins, MD, PhD Session: Genitourinary Cancer (General Poster Session) 3. Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. Meeting: 2006 ASCO Annual Meeting Presenter: Robert E Hawkins Session: Melanoma (Poster Discussion Session) More... /Educational Book Manuscripts by Robert E. Hawkins/: No items found. /This online resource is supported by:/ Terms & Conditions • Privacy Policy • Sponsor • Contact Us • Relationships with Industry • Site Map 2318 Mill Road, Suite 800, Alexandria, VA 22314 | phone: (571) 483-1300 © 2005–2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide. Feedback Form